Bromhexine Hydrochloride for Moderate COVID‐19: The Mucolytic Agent May Help COVID Patients |
Molecule Updates
eMediNexus Coverage from: 
Bromhexine Hydrochloride for Moderate COVID‐19: The Mucolytic Agent May Help COVID Patients

0 Read Comments                

Table. Efficacy outcomes in the study

OutcomeBromhexine groupControl group
Time to fever remission (days, median (interquartile))10.5 (9.3-11)11.5 (9.5-12)
Remarkable/complete improvement in CT (%)66.733.3
Patients requiring oxygen therapy (%)16.733.3
Rate of discharge within 20 days (%)83.333.3

Reference

Li T, Sun L, Zhang W, et al. Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study. Clin Transl Sci. 2020 Nov;13(6):1096-1102.

What is the message here?

Bromhexine could be potentially beneficial in patients with mild to moderate COVID-19 and large-scale clinical trials should be conducted to confirm the same.

To comment on this article ,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now